# Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

> **NCT04134182** · PHASE2 · UNKNOWN · sponsor: **Kidney Cancer Research Bureau** · enrollment: 8 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04134182
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-16
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134182, "Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04134182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*